Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.114.291 |
Chemical and physical data | |
Formula | C22H25N3O2 |
Molar mass | 363.461 g·mol−1 |
3D model (JSmol) | |
|
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems[1][2] but not in human hearts.[3][4] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[5]
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
---|---|---|---|---|---|
Other antagonists |
| ||||
|
α1 |
| ||||
---|---|---|---|---|---|
α2 |
| ||||
β |
| ||||